Daiichi, Lilly sign European agreement for osteoporosis drug Evista

By Elaine Rigoli

Tampa, Fla., July 14 - Daiichi Sankyo Europe GmbH and Eli Lilly and Co. have signed a marketing and distribution agreement for osteoporosis drug Evista (raloxifene) in Germany, Italy, Belgium, the Netherlands, Austria and Switzerland.

Evista, which was developed by Lilly, is a selective estrogen receptor modulator that inhibits bone resorption. In Europe, it is indicated for the treatment and prevention of osteoporosis in post-menopausal women.

Daiichi Sankyo Europe is located in Munich, Germany.

Eli Lilly is an Indianapolis-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.